Nine-field intensity-modulated radiotherapy shortened overall planning-plus-delivery time and improved several pelvic dose metrics compared with volumetric modulated arc therapy.
Deep learning produced machine-deliverable lymphoma plans across heterogeneous anatomy, but target coverage and hot spots remained inferior to reference planning.
Temporally modulated pulsed radiotherapy achieved a median progression-free survival of 27.2 months in large, previously irradiated recurrent meningiomas.
An autoencoder identified anomalous IMRT plans with an area under the curve of 0.98 and explained which parameters drove each alert.
Simultaneous integrated boost radiotherapy was associated with 96% two-year disease-free survival versus 70% with sequential boost in anal cancer.
Three-year locoregional recurrence-free survival was 90.8%, with most locoregional recurrences occurring within or near the radiation field.
All patients receiving more than 8 Gy mean dose or 16 Gy maximum dose to the least exposed ovary developed premature ovarian insufficiency.
Existing thyroid complication models showed moderate performance and frequent miscalibration in long-term head and neck cancer survivorship.
No radiation myelopathy was observed after target-prioritized intensity modulated radiotherapy for selected nasopharyngeal carcinoma near the spinal cord.
Definitive intensity-modulated radiotherapy alone achieved 93.0% three-year overall survival, with no recurrence solely within omitted prophylactic nodal regions.
Anatomy- and dose-based machine learning predicted gamma passing rates accurately for organs at risk, but less reliably for target volumes.